IP Library Granted Patent US 7,604,821
Granted Patent B2
US 7,604,821 · App. 10/659,451 · Granted Oct 20, 2009

Porifera-based therapeutic compositions for treating and preventing skin diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,604,821
App. No.
10/659,451
Granted
Oct 20, 2009
Kind
B2
Abstract

Therapeutic compositions and methods for using same for treating skin conditions and diseases are disclosed. Treatable skin conditions and diseases include, for example, acne vulgaris, rosacea, seborrheic dermatitis, eczema (atopic dermatitis), psoriasis, photo-aging and actinic keratosisacne vulgaris, psoriasis, photo-aging and eczema. Therapeutic compositions disclosed are derived from Porifera species, specifically sponges, and more specifically fresh water sponges. One disclosed embodiment is derived from Spongilla species and is formulated with pharmaceutically acceptable excipients.

Claims (6)

1. A therapeutic composition for treating skin diseases comprising consisting of:

a substantially pure powder of a fresh water sponge, Spongilla lacustris , and at least one pharmaceutically acceptable excipient, wherein said therapeutic composition consists of approximately 50% to 60% insoluble material obtained from said Spongilla lacustris having a maximum particle size of 0.2 mm of said substantially pure powder of Spongilla lacustris.

2. The composition according to claim 1 , wherein said skin disease is selected from the group consisting of acne vulgaris, rosacea, seborrheic dermatitis, atopic dermatitis, psoriasis, photo-aging and actinic keratosis.

3. The composition according to claim 1 , wherein said Spongilla lacustris is harvest from the Arstrakian region of the Russian Federation.

4. The composition of claim 1 , wherein said pharmaceutically acceptable excipient is selected from the group consisting of water, glycerin, gels, oils, waxes, emollients, cleansers, fragrances, antiseptics, anesthetics, seaweed powder, coral powder, hydrogen peroxide, enzyme gel, jojoba oil and boric acid.

5. The composition of claim 4 , wherein said water is selected from the group consisting of water for injection, irrigation water, distilled water, deionized water and floral water.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2017
From: VILLANI, MARIA
To: VILLANI, INC.
Reel/Frame 042620/0503 →
CONFIRMATORY RELEASE OF SECURITY INTEREST IN PATENTS (RELEASES RF 038422-0563) Recorded Jun 6, 2017
From: DERMATA THERAPEUTICS, LLC
To: VILLANI, MARIA
Reel/Frame 042706/0354 →
RELEASE OF SECURITY INTEREST IN PATENTS (RELEASES RF 030747-0207) Recorded Apr 12, 2016
From: PERRICONE, NICHOLAS V., MD
To: VILLANI, MARIA, MD
Reel/Frame 038422/0305 →
PATENT SECURITY AGREEMENT Recorded Apr 12, 2016
From: VILLANI, MARIA, MD
To: DERMATA THERAPEUTICS, LLC
Reel/Frame 038422/0563 →
SECURITY AGREEMENT Recorded Jul 3, 2013
From: VILLANI, MARIA, MD
To: PERRICONE, NICHOLAS V., MD
Reel/Frame 030747/0207 →
Continuity (2)
Continuation In Part 1018699600 · Jul 1, 2002
Related Publication 20040109872A1 · Jun 10, 2004